Price
No data yet.
Social Signal Score
Analyst Ratings
55 analystsRevenue
$401.25MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Michael E. Severino
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 835
- Beta
- 0.20
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -0.01
Financials
Revenue
$401.25M+7301.8%Net Income
$-4.89MEBITDA
$30.17MFree Cash Flow
$-8.25MEPS (diluted)
$-0.05Shares Outstanding (diluted)
105.43M+118.5%Operating Expenses
$198.86MCash & Debt
$788.49MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $2.20B | $-713.41M | $-7.13 |
| 2024 | $1.90B | $235.24M | $2.47 |
| 2023 | $1.24B | $-535.98M | $-5.80 |
| 2022 | $933.01M | $-703.49M | $-8.03 |
| 2021 | $701.89M | $-418.78M | $-5.15 |
| 2020 | $540.10M | $-554.13M | $-7.11 |
| 2019 | $380.83M | $-715.08M | $-9.71 |
| 2018 | $301.03M | $-361.92M | $-5.46 |
| 2017 | $154.58M | $-50.69M | $-0.86 |
| 2016 | $5.42M | $-267.26M | $-5.49 |
| 2015 | $1.25M | $-220.03M | $-5.20 |
| 2014 | $9.76M | $-135.79M | $-3.39 |
| 2013 | $14.22M | $-111.98M | $-3.31 |
| 2012 | $37.33M | $-121.29M | $-5.14 |
Valuation
SRPThas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
120+20.00%Social Signal Score
Mentions (2)
- Newsseekingalpha.com·5h ago·Positive
Sarepta Therapeutics, Inc. (SRPT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Sarepta Therapeutics, Inc. (SRPT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsbenzinga.com·6d ago·Neutral
A Rivals Clinical Stumble Sends Sarepta Therapeutics Stock Lower Sarepta Therapeutics Inc. (NASDAQ:SRPT) stock is trading lower on Tuesday in reaction to Novartis AG's (NYSE:NVS) data from the global Phase 3 HARBOR study of del-desiran for myotonic dystrophy type 1 (DM1).
View source ↗
Earnings
Wed, Nov 4(in 7 weeks)
Consensus estimate $0.17 per share
Typical surprise -123.0% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 5$-0.05 vs $0.22miss
- Wed, May 6$3.16 vs $0.98beat
- Wed, Feb 25$-3.58 vs $-1.03miss
- Mon, Nov 3$-1.80 vs $-0.73miss
- Wed, Aug 6$2.02 vs $0.83beat
- Tue, May 6$-4.60 vs $-0.87miss
Estimates and results for SRPT via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by SRPT officers and directors.
- Bought
- —
- Sold
- $666k
0 trades
3 trades
- Mayo Stephensold
- Estepan Ian Michaelsold
- Nicaise Claudesold
97 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Gilbert Ray Cisneroshouse · CA31 · disclosed May 7, 2025 (23d later)Sell$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Aug 21, 2023 (38d later)Buy$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Jul 11, 2023 (28d later)Sell$1,001 - $15,000
- Daniel Goldmanhouse · NY10 · disclosed May 19, 2023 (39d later)Sell$15,001 - $50,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Apr 20, 2023 (45d later)Buy$1,001 - $15,000
- Daniel Goldmanhouse · NY10 · disclosed Apr 17, 2023 (42d later)Buy$15,001 - $50,000
- Daniel Goldmanhouse · NY10 · disclosed Feb 24, 2023 (24d later)Sell$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Dec 9, 2020 (33d later)Sell$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Oct 14, 2020 (30d later)Buy$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Jul 17, 2020 (37d later)Sell$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Jan 6, 2020 (24d later)Buy$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA39 · disclosed Nov 15, 2019 (35d later)Buy$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA39 · disclosed Nov 15, 2019 (36d later)Buy$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA39 · disclosed May 14, 2019 (35d later)Buy$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA39 · disclosed Apr 16, 2019 (36d later)Buy$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA39 · disclosed Mar 8, 2019 (9d later)Buy$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA39 · disclosed Mar 8, 2019 (10d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.